SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Enviva Inc. (EVA) .
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+13525.5%).
- Analyst consensus target $57.20 (+13525.5% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 35/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — EVA
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.03
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-9.23
Book Value / Share$0.00
Revenue / Share$16.18
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$57.20 (+13525.5%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2014 |
$0.01 |
$290.14M |
$264K |
0.1% |
| 2015 |
$0.96 |
$457.37M |
$23.17M |
5.1% |
| 2016 |
$0.84 |
$464.28M |
$21.38M |
4.6% |
| 2017 |
$0.61 |
$543.22M |
$17.51M |
3.2% |
| 2018 |
$0.25 |
$573.74M |
$6.95M |
1.2% |
| 2019 |
$-1.29 |
$684.39M |
$-43.05M |
-6.3% |
| 2020 |
$0.33 |
$875.08M |
$17.08M |
2% |
| 2021 |
$-2.77 |
$1.04B |
$-145.27M |
-13.9% |
| 2022 |
$-2.51 |
$1.09B |
$-168.37M |
-15.4% |
| 2023 |
$-9.23 |
$1.2B |
$-685.99M |
-57% |
